The Challenge Inbeeo’s client, a mid-sized pharma company, was renewing and relaunching their internal Real-World Evidence capabilities as a cross-functional team. They approached Inbeeo to
The Challenge Inbeeo’s client, a specialty pharmaceutical company, was preparing for the Wave 1 launch of an ‘incremental innovation’ product. They required health economic tools
The Challenge Inbeeo’s client, a leader in a specialty CNS area, were actively preparing for the global launch of two products in quick succession. With
The Challenge Inbeeo’s client, a mid-size biopharmaceutical company, were facing challenges in gaining reimbursement for some of their products across Europe. They had begun to
The Challenge The EU regulatory landscape is evolving, with one of the main changes being the introduction of the Joint Clinical Assessment (JCA). The regulation
The Challenge Inbeeo’s client, a local affiliate of a major global pharmaceutical company, is developing several gene therapy (GTx) products. In advance of their launch
The Challenge Inbeeo’s client, a specialty CNS company, is preparing for the launch of their novel product in a highly competitive indication. There had been extensive
The Challenge Inbeeo’s client was a small clinical stage pharmaceutical company that was developing a novel product to treat Idiopathic Pulmonary Fibrosis (IPF), who were
The Challenge Inbeeo’s client, a specialty pharmaceutical company, is commercializing a novel radiopharmaceutical for an orphan oncology indication in Japan. Pricing mechanisms in Japan presented
The Challenge Our client, a mid-size biopharmaceutical company partnered with Inbeeo to develop a payer value story that can consider different clinical outcomes and be
